| Evidence-based use of levosimendan in different clinical settings. | |
| | |
MedLine Citation:
|
PMID: 16682381 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Levosimendan is a new calcium sensitizer and K-ATP channel opener. Compared with other inodilators, it improves myocardial contractility without increasing oxygen requirements and induces peripheral and coronary vasodilation with a potential anti-stunning, anti-ischaemic effect. The documentation regarding levosimendan is one of the largest ever on the safety and efficacy of a new pharmacological agent in acute heart failure syndromes. Recent experiences in small-scale studies and randomized clinical trials have led to greater interest in the use of this drug for the support of impaired cardiac function also in patients with ischaemic heart disease and cardiogenic or septic shock. It is also demonstrated that this drug could be used as bridge therapy for the peri-operative phase of cardiac surgery in both adult and paediatric populations. This review summarizes the evidence from published scientific literature regarding the use of levosimendan in various clinical settings. |
| | |
Authors:
|
Leonardo De Luca; Wilson S Colucci; Markku S Nieminen; Barry M Massie; Mihai Gheorghiade |
Publication Detail:
|
Type: Journal Article; Review Date: 2006-04-27 |
Journal Detail:
|
Title: European heart journal Volume: 27 ISSN: 0195-668X ISO Abbreviation: Eur. Heart J. Publication Date: 2006 Aug |
Date Detail:
|
Created Date: 2006-08-03 Completed Date: 2007-01-08 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8006263 Medline TA: Eur Heart J Country: England |
Other Details:
|
Languages: eng Pagination: 1908-20 Citation Subset: IM |
Affiliation:
|
Division of Cardiology, European Hospital, Rome, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adult Arrhythmias, Cardiac / chemically induced Cardiotonic Agents / pharmacology, therapeutic use* Child Heart Failure / drug therapy* Humans Hydrazones / pharmacology, therapeutic use* Intraoperative Care Myocardial Ischemia / drug therapy* Pyridazines / pharmacology, therapeutic use* Randomized Controlled Trials as Topic Shock, Cardiogenic / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Cardiotonic Agents; 0/Hydrazones; 0/Pyridazines; 131741-08-7/simendan |
| Comments/Corrections | |
Comment In:
|
Eur Heart J. 2007 Feb;28(4):515
[PMID:
17283001
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Differential change in left ventricular mass and regional wall thickness after cardiac resynchroniza...
Next Document: C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study.